Your shopping cart is currently empty

EIDD-2749 (4'-FlU), a ribonucleoside analog, is an orally available RdRp inhibitor with spectroscopic antiviral activity that interrupts the replication of respiratory syncytial virus and SARS-CoV-2.EIDD-2749 attenuates lethal infections of pandemic human and highly pathogenic avian influenza viruses.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $98 | In Stock | In Stock | |
| 10 mg | $180 | In Stock | In Stock | |
| 25 mg | $392 | In Stock | In Stock | |
| 50 mg | $748 | - | In Stock |
| Description | EIDD-2749 (4'-FlU), a ribonucleoside analog, is an orally available RdRp inhibitor with spectroscopic antiviral activity that interrupts the replication of respiratory syncytial virus and SARS-CoV-2.EIDD-2749 attenuates lethal infections of pandemic human and highly pathogenic avian influenza viruses. |
| In vitro | EIDD-2749 (20 uM) is effective in synthesizing metabolism in HAE cells and is effective on human airway epithelial organoids[1]. |
| In vivo | In Balb/cJ mice (RSV infection model), EIDD-2749 (0.2, 1, 5 mg/kg; oral administration; once daily for 4 days) resulted in a statistically significant reduction in lung virus load[1]. |
| Synonyms | 4'-Fluorouridine, 4'-FlU |
| Molecular Weight | 262.19 |
| Formula | C9H11FN2O6 |
| Cas No. | 1613589-24-4 |
| Smiles | O[C@H]1[C@@H](O[C@@](CO)(F)[C@H]1O)N2C(=O)NC(=O)C=C2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 15 mg/mL (57.21 mM), Sonication is recommended. H2O: 50 mg/mL (190.7 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.63 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
DMSO/H2O
H2O
| |||||||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.